BLDV Acquires 25% of Cann10 North America Holdings Ltd.

Blue Diamond Ventures Inc. CEO Josh Alper appointed to Board of Directors


Chicago, IL. /Toronto, Canada, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Blue Diamond Ventures Inc. (OTC PK: BLDV), has completed the share purchase agreements with Cann10 North America Ltd. to acquire 25% of the shares in the newly formed venture. The acquisition will make BLDV the single largest shareholder in Cann10 North America, and Josh Alper, CEO of BLDV will have one of three seats on the board of directors. $750K in BLDV restricted shares and value added services are slated for this transaction, giving Cann10 North America an initial valuation of $3MM.

Cann10 North America Holding Ltd. is involved in the following activities:

  • Expanding Trade and Business Activities of Cann10 to USA, Canada, Mexico, and Caribbean
  • Offering Medical Cannabis Education and Courses in partnership with leading Universities.
  • Offering new Investment Opportunities in Targeted Therapies & Medical Devices.
  • Running the industry’s premiere Medical Cannabis Industry Conferences in North America.

“Cann10 North America is actively securing strategic partners” says Josh Alper, BLDV CEO. “This project touches everything we do and allows us to effectively use our network of trusted parties. Together we can provide education, access to investment in technologies and conferences all based on hard science and leading-edge research”.

The acquisition completes a promise made to BLDV shareholders to set the stage for significant revenue creation in 2018, with Global Partners focused on leading-edge Cannabis Research, Production and Clinical Trials.

The new company, located in Canada has already captured the attention of multiple Licensed Producers (LP’s) in the rapidly expanding Canadian Cannabis Market, and has had offers of equity positions, consulting services, and more, based on access to the Israeli pipeline of products and IP, and the strong background of the team in providing Medical Education in the Global Cannabis Market.

Yossi Bornstein, CEO of Shizim Ltd, and Chairman of Cann10 International, stated "Blue Diamond Ventures offered us a unique combination of experience and knowledge for the North American market”.

The acquisition of shares in Cann10 North America, is in addition progress made on the other two main areas of focus by BLDV, Building and Leasing of facilities through the Innovative Growth Group (formally Michigan Growth Fund) and the newly re-launched Cannabis Sanitation efforts.

“The new tax laws favour the way our real-estate model is setup” said Jonathan Alper, Director in BLDV, Licensed Landscape Architect and the Master Planner for the real estate effort, “we could get up to an additional 5% return for our investors on the projects that are already forecasted.”

BLDV shares have shown significant movement this year and the operating divisions of the company are  poised to become some of the leaders in the Medical Cannabis arena, corporate focus on the Adult-Use markets in both the USA and Canada, has opened Medical Cannabis opportunities for companies like BLDV and their strategic partners Cann10, AMS, Quality Green Inc., and others.

About BLDV:

BlueDiamond Ventures,Inc. is adiversified customer centric Management /Holding Company;BlueDiamond Ventures,Inc. seeks opportunities inmedical cannabis marketsand is driven by critical thinking, the scientific method and compassionate ways to deliver sustainable results

About Cann10:

Cann10 is a medical cannabis focused accelerator, offering selected entrepreneurs the advantages of high quality infrastructures, facilities, team, network, know-how and professional mentoring, tailored to support successful development, fund raising and commercialization of new technologies in this emerging field.

A collaboration between a leading Israeli authorized medical cannabis farm, and a leading Israeli holding and services group, Cann10 combines the respective expertise in the fields of medical cannabis and commercialization of medical devices and drugs, to support the introduction of new high value related products.


FORWARD LOOKING STATEMENT

This press release contains certain “forward‐looking” statements, as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward‐looking statements. The Company, through its management, makes forward‐looking public statements concerning it expected future operations, performance and other developments. Such forward‐looking statements are necessarily estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no factors that could cause actual results to differ materially from those estimated by the Company. They include, but are not limited to, the Company’s ability to develop operations, the Company’s ability to consummate and complete the acquisition, the Company’s access to future capital, the successful integration of acquired companies, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, sales and other factors that may be identified from time to time in the Company’s public announcements.

Source: Uptick Newswire


            

Coordonnées